Clinical Trials

Question 1

ADMIRAL Trial

Answer 1

This trial looks at the administration of gilteritinib monotherapy compared to salvage chemotherapy in patients with R/R Flt3 mutated AML.

Question 2

RATIFY Trial

Answer 2

This trial looks at the administration of chemotherapy and midostaurin at the Induction setting for Flt3 mutant AML patients.

Question 3

GALLIUM Trial

Answer 3

This trial looks at obinutuzumab and chemotherapy vs rituximab and chemotherapy followed by obinutuzumab or rituximab maintenance therapy in advanced or indolent non-hodgkin lymphoma.

Question 4

SORAML Trial

Answer 4

This trial looks at the effect of sorafenib with standard chemotherapy in newly diagnosed AML patients.

Question 5

HOVON 156 AML Trial

Answer 5

This trial is designed to compare midostaurin and chemotherapy vs gilteritinib and chemotherapy at both the Induction and Consolidation setting followed by 1 year maintenance in Flt3 mutant AML patients.

Question 6

CHRYSALIS Trial

Answer 6

This is a phase 1 trial that looks at dose escalation and dose expansion of gilteritinib monotherapy in R/R AML patients where Flt3 mut is not an inclusion criteria. The dose escalation part targets an Maximum Tolerated Dose (MTD) while the dose expansion part looks at associated toxicities and pharmacokinetics.

Question 7

HAVEN 3 Trial

Answer 7

This is a phase 3 trial that looks at emicizumab prophylactic treatment targeting Blood Clotting Factor VIII in Hemophilia A.

Question 8

CLL-14 Trial

Answer 8

This trial looks at the effect of venetoclax and obinutuzmab vs chlorambucil and obinutuzumab in patients with CLL at the induction setting.

Question 9

CAPTIVATE Trial

Answer 9

This trial looks at the effect of venetoclax and ibrutinib in Treatment Naive Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

Question 10

INO-VATE Trial

Answer 10

This trial looks at the effect of CD22 antibody drug conjugate Inotuzumab Ozogamicin on R/R ALL.

Question 11

kaRMMa Trial

Answer 11

This trial looks at the effect of Idecil (BCMA CAR T Cell Therapy) in patients with multiple myeloma.

Question 12

SKYSCRAPER-01 Trial

Answer 12

This is a phase III trial looking at tirogolumab and atezolizumab vs atezolizumab as an initial first line treatment for high PD-L1 high or locally advanced non small cell lung cancer.

Question 13

CITYSCAPE Trial (Tiragolumab + Atezolezumab)

Answer 13

This combination is not FDA approved yet but its effect on non small cell lung cancer is being evaluated. Better Objective Response and PFS reported compared with placebo in this randomized phase II trial.

Question 14

HELIOS Trial

Answer 14

This is a phase 3 trial where ibrutinib is added to rituximab and bendamustine in relapsed/refractory CLL.

Question 15

CANOVA Trial

Answer 15

This is a trial where Venetoclax and Dexamethasone is compared with Pomalidomide and Dexamethasone in relapsed or refractory multiple myeloma.

Question 16

BELLINI Trial

Answer 16

This is a phase 3 trial that examines a combination of Venetoclax, Bortezomib and Dexamethasone in relapsed or refractory multiple myeloma.

Question 17

VIALE-A Trial

Answer 17

This is a trial of Venetoclax and Azacytidine vs placebo on patients with previously untreated AML who were ineligible to standard chemotherapy because of having comorbidities or who were 75yrs and older.

Question 18

TOWER Trial

Answer 18

This study looks at the effect of blinatumomab vs SOC chemotherapy for patients with R/R ALL.

Question 19

MURANO Trial

Answer 19

This trial compares the effects of venetoclax and rituximab vs bendamustine and rituximab at the R/R setting in CLL.

Question 20

RESONATE Trial

Answer 20

This trial compares ibrutinib with monoclonal antibody for CD20 ofatumumab. Ibrutinib showed better OR and OS than ofatumumab.

Question 21

CLL10 Trial

Answer 21

This is a trial where chemoimmunotherapy - bendamustine and rituximab vs FCR (Fludarabine, Cyclophosphamide and Rituximab) in patients with advanced CLL is assessed.

Question 22

AC220-002 Trial

Answer 22

This is a multi-center phase 2 study looking at single agent quizartinib on adult patients having R/R AML.

Question 23

AMLSG 16-10

Answer 23

This is a phase 2 trial which is similar in design to the RATIFY trial but patients can undergo midostaurin vs control agent as maintenance therapy after allogenic stem cell transplant.

Question 24

SORMAIN Trial

Answer 24

This trial is similar in design to the AMLSG 16-10 trial but the TKI used in this case is sorafenib instead of midostaurin post transplant.

Question 25

RADIUS Trial

Answer 25

This trial is similar to the AMLSG 16-10 design but midostaurin vs SOC is used as opposed to midostaurin vs control treatment after allogenic stem cell transplant for Flt3ITD positive AML patients. There was no goal for treatment benefit.